The stock of TG Therapeutics Inc (NASDAQ:TGTX) is a huge mover today! About 313,064 shares traded hands or 5.33% up from the average. TG Therapeutics Inc (NASDAQ:TGTX) has declined 14.71% since March 7, 2016 and is downtrending. It has underperformed by 22.30% the S&P500.
The move comes after 6 months positive chart setup for the $513.72M company. It was reported on Oct, 10 by Barchart.com. We have $14.15 PT which if reached, will make NASDAQ:TGTX worth $277.41 million more.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on November, 14. They expect $-0.32 earnings per share, down 14.29% or $0.04 from last year’s $-0.28 per share. After $-0.33 actual earnings per share reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.03% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of TG Therapeutics Inc (NASDAQ:TGTX) earned “Strong Buy” rating by Raymond James on Wednesday, September 9. The company was initiated on Tuesday, December 1 by FBR Capital. On Wednesday, August 12 the stock rating was upgraded by Zacks to “Hold”. Suntrust Robinson initiated TG Therapeutics Inc (NASDAQ:TGTX) on Friday, May 27 with “Buy” rating. The rating was reinitiated by Brean Capital with “Buy” on Thursday, October 6. The rating was initiated by SunTrust with “Buy” on Friday, May 27. H.C. Wainwright reinitiated the shares of TGTX in a report on Wednesday, August 12 with “Buy” rating.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio increased, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Ubs Asset Americas owns 1.81 million shares or 0.01% of their US portfolio. California Public Employees Retirement System last reported 124,800 shares in the company. American Interest Gp Inc holds 0% or 21,204 shares in its portfolio. Voya Invest Management Ltd accumulated 14,870 shares or 0% of the stock. Legal And General Group Inc Inc Public Limited Co has 7,185 shares for 0% of their US portfolio. Gru One Trading Ltd Partnership has invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). Art Limited Com owns 88,654 shares or 0.03% of their US portfolio. Vanguard Grp last reported 0% of its portfolio in the stock. Eventide Asset Limited holds 0.2% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX) for 537,600 shares. Moreover, Kcg Hldgs Incorporated has 0.01% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 43,326 shares. Mariner Wealth Advisors Ltd Liability Co has 0.01% invested in the company for 19,086 shares. Nationwide Fund Advsrs reported 108,904 shares or 0% of all its holdings. Ladenburg Thalmann Fincl Services has 2,539 shares for 0% of their US portfolio. Secor Capital Advsr Limited Partnership holds 30,820 shares or 0.02% of its portfolio. Blackrock Gru holds 0% or 17,275 shares in its portfolio.
Insider Transactions: Since April 18, 2016, the stock had 0 insider purchases, and 2 sales for $403,252 net activity. On Monday, April 18 the insider Power Sean A sold $101,200.
More news for TG Therapeutics Inc (NASDAQ:TGTX) were recently published by: Globenewswire.com, which released: “TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2016 Healthcare …” on August 26, 2016. Fool.com‘s article titled: “The Reason Behind TG Therapeutics Inc.’s Soaring Stock Price” and published on June 18, 2015 is yet another important article.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.